title: Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
abstract: BACKGROUND
  This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients.
  
  
  METHODS
  A total of 150 patients were randomly assigned to receive either oral temozolomide (200 mg m(-2) per day; days 1-5) or intravenous dacarbazine (800 mg m(-2); day 1), in combination with intravenous cisplatin (75 mg m(-2); day 1) and subcutaneous interleukin-2 (3 MU twice daily; days 9-18), every 28 days (CTI and CDI).
  
  
  RESULTS
  A total of 149 patients were eligible for an intention-to-treat analysis (CTI: n=74, CDI: n=75). The 1-year cumulative CNS incidence failure was 20.6% for CTI and 31.1% for CDI (P=0.22). In all 24 patients in CTI (32%) and 34 (45%) in CDI developed CNS metastases; 31 patients died of early systemic progression, before CNS evaluation. Median survival time was 8.4 months in the CTI and 8.7 in the CDI arm; in patients with CNS metastases the median survival time was 13.5 months in the CTI and 11.5 in the CDI arm. No difference in toxicity was observed between the two arms.
  
  
  CONCLUSIONS
  The incidence of CNS failures in metastatic melanoma was not significantly reduced and the clinical course was not modified substituting a dacarbazine-based regimen with a temozolomide-based regimen. Patients who developed CNS metastases did not have a worse prognosis than patients progressing in other sites and should not be excluded from new investigational studies.
authors: Melanoma and Skin Cancer Unit, Istituto Oncologico Veneto IOV-IRCCS, via Gattamelata 64, Padova 35128, Italy. mgaliz@tiscali.it
authors: V
authors: V
authors: Chiarion-Sileni
authors: M
authors: M
authors: Guida
authors: L
authors: L
authors: Ridolfi
authors: A
authors: A
authors: Romanini
authors: P
authors: P
authors: Del Bianco
authors: J
authors: J
authors: Pigozzo
authors: S
authors: S
authors: Brugnara
authors: G
authors: G
authors: Colucci
authors: R
authors: R
authors: Ridolfi
authors: G L
authors: GL
authors: De Salvo
references: J Histochem Cytochem. 1990 Sep;38(9):1277-87
references: 1974900
references: J Pharmacol Exp Ther. 2000 Aug;294(2):664-71
references: 10900246
references: Melanoma Res. 2004 Aug;14(4):295-9
references: 15305161
references: Am J Pathol. 1996 Sep;149(3):853-8
references: 8780389
references: J Chemother. 1995 Jun;7(3):224-9
references: 7562019
references: Melanoma Res. 2002 Apr;12(2):175-8
references: 11930115
references: J Clin Oncol. 2007 Dec 1;25(34):5426-34
references: 18048825
references: J Clin Oncol. 2000 Jan;18(1):158-66
references: 10623706
references: Cancer. 2003 Jun 15;97(12):2972-7
references: 12784331
references: J Clin Oncol. 2002 Apr 15;20(8):2045-52
references: 11956264
references: J Natl Compr Canc Netw. 2006 Aug;4(7):666-84
references: 16884669
references: J Clin Oncol. 1999 Jul;17(7):2105-16
references: 10561265
references: J Clin Oncol. 2007 Jun 1;25(16):2306-12
references: 17538177
references: J Clin Oncol. 2002 Mar 15;20(6):1600-7
references: 11896110
references: Clin Cancer Res. 1999 Jul;5(7):1629-37
references: 10430061
references: Melanoma Res. 2010 Apr;20(2):141-6
references: 20075758
references: Int J Clin Oncol. 2009 Feb;14(1):48-52
references: 19225924
references: Clin Cancer Res. 2002 Oct;8(10):3075-81
references: 12374674
references: Oncology (Williston Park). 2009 May;23(6):488-96
references: 19544689
references: Melanoma Res. 2006 Feb;16(1):59-64
references: 16432457
references: Ann Oncol. 2005 Jun;16(6):950-7
references: 15829494
references: Am J Clin Oncol. 2005 Oct;28(5):479-84
references: 16199988
references: J Clin Oncol. 2005 Dec 10;23(35):8992-9000
references: 16260693
references: J Clin Oncol. 2004 Jul 15;22(14):2865-72
references: 15254054
references: J Clin Oncol. 2001 Aug 15;19(16):3635-48
references: 11504745
references: Melanoma Res. 2006 Feb;16(1):65-9
references: 16432458